

CITATION REPORT

List of articles citing

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

DOI: 10.1200/jco.2005.12.187

Journal of Clinical Oncology, 2005, 23, 3343-51.

Source: <https://exaly.com/paper-pdf/38784059/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
121	Is there a role for chemotherapy in prostate cancer?. 2004 , 91, 1005-11		16
120	Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. 2005 , 10 Suppl 3, 30-9		29
119	Prostate cancer chemotherapy: emerging from the shadows. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3302-3322		11
118	In Reply:. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8125-8126	2.2	1
117	Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. 2005 , 28, 573-8		8
116	Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8124-5; author reply 8125-6	2.2	3
115	Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. 2006 , 5, 212-8		4
114	Hormone refractory prostate cancer: Management and advances. 2006 , 32, 90-100		24
113	Chemotherapy for hormone-refractory prostate cancer. 2006 , CD005247		46
112	A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. <i>BJU International</i> , 2006 , 98, 580-5	5.6	13
111	A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. 2006 , 95, 457-62		18
110	[Therapeutic options for hormone-refractory prostate cancer]. 2006 , 45, 580, 582-5		
109	Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. 2006 , 107, 738-45		31
108	Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2828-35	2.2	73
107	Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. 2007 , 13, 1208-15		58
106	Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. 2007 , 18, 1828-33		46
105	Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. <i>American Journal of Roentgenology</i> , 2007 , 189, 830-44	5.4	65

104	Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. 2007 , 18, 1064-70		43
103	Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial. 2007 , 25, 207-13		2
102	Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. 2007 , 110, 996-1002		16
101	The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. 2007 , 67, 955-67		106
100	Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria. 2007 , 67, 1543-9		10
99	Potential of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. 2007 , 96, 269-76		23
98	Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. 2007 , 97, 1206-10		17
97	Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. 2007 , 97, 1613-7		5
96	Preliminary results of the Prostateox phase II trial in hormonal refractory prostate cancer. <i>BJU International</i> , 2007 , 100, 770-4	5.6	11
95	Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. 2008 , 61, 53-61		2
94	Cancer avancé de la prostate et maladie osseuse métastatique. 2007 , 9, 564-572		
93	Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients. 2007 , 9, 323-8		3
92	Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. 2007 , 61, 176-85		35
91	Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. 2008 , 40, 97-104		29
90	Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). <i>Investigational New Drugs</i> , 2008 , 26, 75-9	4.3	15
89	Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. 2008 , 113, 966-74		17
88	Perspectives thérapeutiques des métastases osseuses de cancer prostatique. 2008 , 75, 343-351		
87	Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. <i>BJU International</i> , 2008 , 102, 1080-5	5.6	28

86	Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. <i>BJU International</i> , 2008 , 102, 1607-9	5.6	21
85	Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. 2008 , 23, 137-57		36
84	Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5261-8	2.2	67
83	Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. 2008 , 20, 509-12		21
82	Systemic nonhormonal management of advanced prostate cancer and its likely impact on patientsR survival and quality of life. 2008 , 19, 645-53		7
81	Combining docetaxel with estramustine: back to the future?. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1148-9; author reply 1149-50	2.2	3
80	Prostatakarzinom. 2009 , 485-635		
79	Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2429-35	2.2	135
78	Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. 2009 , 56, 479-84		79
77	Editorial comment on: Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. 2009 , 56, 484-5		
76	Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. 2009 , 14, 130-5		13
75	Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. 2009 , 69, 1448-59		62
74	Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. 2009 , 69, 1579-85		76
73	PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. 2009 , 69, 1802-7		35
72	Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. 2009 , 11, 443-50		16
71	Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. 2009 , 16, 687-91		17
70	What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?. <i>BJU International</i> , 2009 , 103, 1641-6	5.6	27
69	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. 2009 , 3, 133-145		2

68	Advances in the Therapy of Prostate Cancer-Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways. 2009 , 8, 747-752		2
67	Chemotherapy in patients with castration-resistant prostate cancer. 2009 , 45 Suppl 1, 161-71		10
66	Tumours of the urogenital tract. 2009 , 151-171		8
65	In Reply. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1149-1150	2.2	2
64	Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer. 2010 , 3, 121-7		2
63	A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer. 2010 , 21, 927-31		3
62	Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. 2010 , 27, 363-7		48
61	Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. 2010 , 27, 19-23		18
60	Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. 2010 , 126, 2826-34		18
59	In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. 2010 , 73, 1342-54		31
58	Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer. 2010 , 76, 1085-91		5
57	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. 2010 , 70, 48-60		23
56	New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. 2010 , 70, 825-33		30
55	Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. <i>BJU International</i> , 2010 , 106, 974-8	5.6	66
54	A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. 2010 , 1, 908-16		72
53	Modified intention to treat reporting in randomised controlled trials: systematic review. 2010 , 340, c2697		130
52	[Update on the use of estramustin in metastatic prostate cancer]. 2010 , 20, 24-9		1
51	Molecular and traditional chemotherapy: a united front against prostate cancer. 2010 , 293, 1-14		17

50	Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. 2010 , 28, 152-6		16
49	Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. 2010 , 97, 312-7		29
48	PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFB and PPAR α 2011 , 55, 202-10		52
47	The use of estramustine phosphate in the modern management of advanced prostate cancer. <i>BJU International</i> , 2011 , 108, 1782-6	5.6	30
46	Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. 2011 , 9, 130-2		1
45	Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. 2011 , 11, 517		32
44	Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. 2011 , 71, 1810-7		21
43	Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. 2011 , 112, 2125-37		19
42	A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. 2011 , 17, 2301-13		46
41	Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer. 2012 , 6, 67-73		7
40	The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. 2012 , 39, 573-81		3
39	Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. 2012 , 72, 1559-77		38
38	Prostate Cancer. 2012 , 377-402		
37	[Management of advanced prostate cancer in elderly patients]. 2012 , 99 Suppl 1, S21-9		
36	Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. 2012 , 28, 269-77		23
35	A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy. 2013 , 6, 1-9		29
34	Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. 2013 , 31, 733-8		21
33	Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy. 2013 , 72, 1055-61		1

32	Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer. 2013 , 11, 78-84		2
31	Synthesis and in vitro studies of gold nanoparticles loaded with docetaxel. 2013 , 454, 703-11		27
30	Unmet needs in the prediction and detection of metastases in prostate cancer. 2013 , 18, 549-57		30
29	Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer. 2013 , 28, 326-8		3
28	Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea. 2014 , 10, 251-7		2
27	Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy. 2014 , 93, 49-54		6
26	Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. 2014 , 19, 165-72		6
25	Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. 2014 , 19, 157-64		10
24	Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. 2014 , 5, e1210		17
23	Importance of ABCC1 for cancer therapy and prognosis. 2014 , 46, 325-42		35
22	Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. 2015 , 3, 123-6		1
21	Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients. <i>Urological Science</i> , 2015 , 26, 267-270	0.3	2
20	Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015 , 115, 744-52	5.6	40
19	Noncolorectal, Nonneuroendocrine Liver Metastases. 2015 ,		
18	Reconsideration of Hormonal Therapy in the Era of Next- Generation Hormonal Therapy. 2016 ,		
17	Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2016 , 34, 474-80	4.3	8
16	Castration Resistant Prostate Cancer: Role of Chemotherapy. 2016 , 509-514		
15	A systematic review of the impact of pain on overall survival in patients with cancer. <i>Supportive Care in Cancer</i> , 2017 , 25, 1687-1698	3.9	33

14	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 419-430	6.2	1
13	The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. <i>International Journal of Surgery</i> , 2018 , 56, 133-140	7.5	7
12	Radioligand Therapy With Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2019 , 213, 275-285	5.4	80
11	Can docetaxel combined prednisone effectively treat hormone refractory prostate cancer?: A protocol of systematic review and meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e20367	1.8	
10	Metastatic Prostate Cancer. 293-303		2
9	Peptides for Radionuclide Therapy. 2008 , 117-144		4
8	Physical activity and genitourinary cancer survivorship. <i>Recent Results in Cancer Research</i> , 2011 , 186, 217-236		15
7	Prostate Cancer. 2008 , 1653-1699		3
6	Chemotherapy for hormone-resistant prostate cancer: Where are we today?. <i>Indian Journal of Urology</i> , 2007 , 23, 55-60	0.8	
5	Prostatakarzinom. 2014 , 513-676		
4	Liver Metastases from Prostate Cancer. 2015 , 183-206		
3	Tumeurs urologiques du sujet âgé. 2007 , 165-178		
2	Prostatakarzinom. 2014 , 513-676		0
1	Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1009-1022	2.5	0